Stuttgart - Delayed Quote EUR

Plus Therapeutics Inc (XMP0.SG)

Compare
0.9490 -0.0570 (-5.67%)
At close: December 19 at 8:16:45 AM GMT+1
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for XMP0.SG

Recent News: XMP0.SG

View More
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire 2 days ago
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium

Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire 15 days ago
Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply

Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply
GlobeNewswire 16 days ago
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis

CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis
Medical Device Network 24 days ago
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
GlobeNewswire 24 days ago
Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
GlobeNewswire 27 days ago
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
GlobeNewswire 28 days ago
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations
Simply Wall St. last month
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
GuruFocus.com last month
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire last month
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates

ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
Zacks last month
View More

Related Tickers

UKJ2.DU Opthea Ltd. R
3.0200
+3.42%
 
OEZ.DU Avecho Biotechnology Ltd
0.0005
-50.00%
 
W2J.MU CARISMA Therapeutics Inc
0.4342
0.00%
 
CLA.MU Akari Therapeutics PLC R
0.9300
0.00%
 
ECQ.F
 
PQ6.F Starpharma Holdings Limited
0.0535
+1.90%
 
G1G.SG Zelira Therapeutics Ltd
0.3580
+1.70%
 
MDBBF Medlab Clinical Limited
15.75
0.00%
 
E4NA.SG Arovella Therapeutics Ltd
0.0970
0.00%
 
ETXPF e-therapeutics plc
0.1300
0.00%